There were no statistically significant differences between the @ study arms with regard to : @ ) peripheral neurotoxicity , as assessed using both the EORTC-QLQ-CIPN@ ( P = @ ) and the CTCAE scales ( P = @ for grade @ neurotoxicity ; P = @ for time to development of grade @ neuropathy , in favor of the placebo ) ; @ ) the degree of paclitaxel acute pain syndrome ( P = @ for patients who received paclitaxel every @-@ weeks and P = @ , in favor of the placebo , for patients who received weekly paclitaxel ) ; @ ) the time to disease progression ( P = @ ) ; or @ ) apparent toxicities .